KEY TAKEAWAYS
- The study aimed to investigate the development and validation of an LC-MS/MS method for ruxolitinib in hematologic malignancies.
- Researchers concluded that the LC-MS/MS method enhances personalized ruxolitinib treatment in hematologic malignancies.
Hematologic malignancies such as leukemia and lymphoma present treatment challenges due to their genetic and molecular heterogeneity. Ruxolitinib, a Janus kinase (JAK) inhibitor, has demonstrated efficacy in managing these cancers.
However, optimal therapeutic outcomes are contingent upon maintaining drug levels within a therapeutic window, highlighting the necessity for precise drug monitoring.
Na Li and the team aimed to focus on developing and validating a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantification of ruxolitinib in biological samples.
They conducted an inclusive analysis by developing a sensitive LC-MS/MS method for quantifying ruxolitinib in human plasma, surpassing traditional methods in terms of specificity, sensitivity, and efficiency.
Advanced chromatographic techniques and robust mass spectrometric conditions were used to ensure high accuracy and minimal matrix effects. The study utilized samples from 20 patients undergoing treatment, with calibration standards set between 10 and 2000 ng/mL.
The method displayed linearity (R2 > 0.99) across the studied range and proved highly selective with no significant interference observed. The method’s precision and accuracy met FDA guidelines, with recovery rates consistently exceeding 85%. The clinical application demonstrated significant variability in ruxolitinib plasma levels among patients, reinforcing the need for individualized dosing schedules.
The study concluded that the validated LC-MS/MS method provides a reliable and efficient tool for therapeutic drug monitoring of ruxolitinib, facilitating personalized treatment approaches in hematologic malignancies. This approach promises to enhance patient outcomes by optimizing dosing to reduce toxicity and improve efficacy.
The study received no funds.
Source: https://pubmed.ncbi.nlm.nih.gov/39007093/
Li N, Zhang H, Bai H, et al. (2024). “Development and validation of an LC-MS/MS method for ruxolitinib quantification: advancing personalized therapy in hematologic malignancies.” J Pharm Pharm Sci. 2024 Jun 28;27:12905. doi: 10.3389/jpps.2024.12905. PMID: 39007093; PMCID: PMC11239354.
